<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852176</url>
  </required_header>
  <id_info>
    <org_study_id>Best PMA Post-approval Study</org_study_id>
    <nct_id>NCT00852176</nct_id>
  </id_info>
  <brief_title>Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System</brief_title>
  <official_title>Best Vascular P000018 Post-approval Study: Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Best Vascular, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Best Vascular, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the long-term safety and efficacy of intravascular beta radiation&#xD;
      therapy to treat coronary in-stent restenosis using the Beta-Cath(TM) 3.5F System; data will&#xD;
      be collected retrospectively on patients treated with the Beta-Cath™ 3.5F System in routine&#xD;
      clinical practice following FDA pre-market approval of the System. Outcomes will be reported&#xD;
      up to 5 years following treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>In-hospital and at 30 days, 6 months, 1, 2, 3, 4 and 5 years post-treatment</time_frame>
    <description>Major Adverse Cardiac Events (MACE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of device-related procedural events</measure>
    <time_frame>At time of intervention</time_frame>
    <description>Incidence of device-related procedural events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success, including successful delivery of the Beta-Cath(TM) 3.5F System radiation source train, return of the radiation source train, and delivery of the intended dose</measure>
    <time_frame>At time of intervention</time_frame>
    <description>Device success, including successful delivery of the Beta-Cath(TM) 3.5F System radiation source train, return of the radiation source train, and delivery of the intended dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 months; 1, 2, 3, 4, and 5 years post-treatment</time_frame>
    <description>Target Vessel Revascularization (TVR)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary In-stent Restenosis</condition>
  <arm_group>
    <arm_group_label>On-label treatment</arm_group_label>
    <description>Patients treated in routine clinical practice following FDA Pre-Market Approval of the Beta-Cath(TM) 3.5F System within the parameters of the approved indications for use for the System (&quot;on-label&quot;).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated on-label with the Beta-Cath™ 3.5F System at Washington Hospital Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent on-label treatment (as defined below) with the Beta-Cath™ 3.5F&#xD;
             System (30, 40 or 60mm) for in-stent restenosis (ISR) after coronary stenting.&#xD;
&#xD;
               1. On-label treatment for the 30 and 40mm Beta-Cath™ 3.5F System is defined as:&#xD;
                  treatment of ISR in native coronary arteries with discrete lesions (treatable&#xD;
                  with a 20mm balloon) in reference vessel diameters (RVD) ranging from 2.7mm to&#xD;
                  4.0mm&#xD;
&#xD;
               2. On-label treatment for the 60mm Beta-Cath™ 3.5F System is defined as: treatment&#xD;
                  of ISR in native coronary arteries with lesions &lt;40mm in length in RVD ranging&#xD;
                  from 2.7mm to 4.0mm&#xD;
&#xD;
          -  Patients must have undergone brachytherapy treatment at least 6-8 months prior to&#xD;
             enrollment in this retrospective study and the date of their treatment must be:&#xD;
&#xD;
               1. On or after February 8, 2002 for the 30/40mm 3.5F System&#xD;
&#xD;
               2. On or after June 25, 2003 for the 60mm 3.5F System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not give informed consent&#xD;
&#xD;
          -  Patients who do not meet the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Waksman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Torguson, MPH</last_name>
    <phone>202-877-2194</phone>
    <email>rebecca.torguson@medstar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington Hospital Center / Cardiovascular Research Institute (CRI)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Torguson, MPH</last_name>
      <phone>202-877-2194</phone>
      <email>rebecca.torguson@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lowell Satler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Kent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Suddath, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary brachytherapy</keyword>
  <keyword>Coronary restenosis</keyword>
  <keyword>Coronary in stent restenosis</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

